NCT07491289

GS1-144 in Participants With Hepatic Impairment and Healthy Female

Pharmacokinetic Study of GS1-144 Tablets in Female Participants With Hepatic Impairment and Healthy Female Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

GS1-144 in Participants with Hepatic Impairment and Healthy Female

Detailed description

Pharmacokinetic Study of GS1-144 Tablets in Female Participants with Hepatic Impairment and Healthy Female Participants

Conditions

• Hepatic Impairment and Healthy Female

Interventions

Type	Name	Description
DRUG	GS1-144 tablet	Administered a single oral dose with GS1-144 tablet 30mg

Timeline

• Start date: 2026-04-20
• Primary completion: 2027-01-31
• Completion: 2027-06-30
• First posted: 2026-03-24
• Last updated: 2026-03-24

Locations

1 site across 1 country: China